[
  {
    "Column": "record",
    "Description": "record: Record number",
    "Answer_Options": "NA"
  },
  {
    "Column": "uuid",
    "Description": "uuid: Participant identifier",
    "Answer_Options": "NA"
  },
  {
    "Column": "date",
    "Description": "date: Completion time and date",
    "Answer_Options": "NA"
  },
  {
    "Column": "status",
    "Description": "status: Participant status",
    "Answer_Options": "1=Terminated,2=Overquota,3=Qualified,4=Partial"
  },
  {
    "Column": "hCALLPLAN",
    "Description": "hCALLPLAN: CALL PLAN",
    "Answer_Options": "1=YES,2=NO"
  },
  {
    "Column": "hTreater",
    "Description": "hTreater: TREATER",
    "Answer_Options": "1=YES,2=NO"
  },
  {
    "Column": "S2a",
    "Description": "S2a: Please read the following requirements carefully. During the market research, should you raise a product complaint, an adverse event, or any other safety information in a patient or group of patients, we will need to report this complaint or event al",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S2b",
    "Description": "S2b: Please read the following requirements carefully, as well. Information presented during this market research study should be treated as confidential and hypothetical information and may only be used to participate in this market research survey. Info",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S3",
    "Description": "S3: Are you, or is any immediate family member, employed by any of the following? Any government agency, including any regulatory bodies overseeing healthcare in your country A marketing research or consulting firm or the marketing department of any compa",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S4",
    "Description": "S4: In which state do you have your license to practice?",
    "Answer_Options": "1=Alaska,2=Alabama,3=Arkansas,4=Arizona,5=California,6=Colorado,7=Connecticut,8=District of Columbia,9=Delaware,10=Florida,11=Georgia,12=Hawaii,13=Iowa,14=Idaho,15=Illinois,16=Indiana,17=Kansas,18=Kentucky,19=Louisiana,20=Massachusetts,21=Maryland,22=Maine,23=Michigan,24=Minnesota,25=Missouri,26=Mississippi,27=Montana,28=North Carolina,29=North Dakota,30=Nebraska,31=New Hampshire,32=New Jersey,33=New Mexico,34=Nevada,35=New York,36=Ohio,37=Oklahoma,38=Oregon,39=Pennsylvania,40=Rhode Island,41=South Carolina,42=South Dakota,43=Tennessee,44=Texas,45=Utah,46=Virginia,47=Vermont,48=Washington,49=Wisconsin,50=West Virginia,51=Wyoming"
  },
  {
    "Column": "REGION",
    "Description": "REGION: HIDDEN QUESTION FOR REGION",
    "Answer_Options": "1=Northeast,2=South,3=Midwest,4=West"
  },
  {
    "Column": "S5a",
    "Description": "S5a: What is your role/title?",
    "Answer_Options": "1=Physician,2=Nurse Practitioner,3=Physician’s Assistant,4=Registered Nurse,5=Medical Assistant,6=Other"
  },
  {
    "Column": "S5b",
    "Description": "S5b: [pipe:S5aPipe]",
    "Answer_Options": "1=Family Practice, General Practice, Internal Medicine, or Primary Care,2=Psychiatry,3=Pediatrics,4=Immunology,5=Allergy,6=Dermatology,7=Other"
  },
  {
    "Column": "S6a",
    "Description": "S6a: Are you board-certified or board-eligible in your medical specialty?",
    "Answer_Options": "1=Board-certified,2=Board-eligible,3=Neither"
  },
  {
    "Column": "S6b",
    "Description": "S6b: Do you have prescribing privileges at the treatment setting in which you work?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S7",
    "Description": "S7: [pipe:S7Pipe]",
    "Answer_Options": "NA"
  },
  {
    "Column": "S8r1",
    "Description": "S8r1: Federally Qualified Health Center (FQHC) / Community Health Center (CHC) - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r2",
    "Description": "S8r2: Solo outpatient private practice - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r3",
    "Description": "S8r3: Single-specialty group outpatient private practice - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r4",
    "Description": "S8r4: Multi-specialty group outpatient private practice - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r5",
    "Description": "S8r5: Inpatient hospital or psychiatric institution - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r6",
    "Description": "S8r6: Nursing home / long-term care facility - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r7",
    "Description": "S8r7: Emergency room or acute care center - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r8",
    "Description": "S8r8: Other setting - What percent of your professional time is spent in each of the following practice settings? Your answer should sum to 100%. Please estimate to the best of your ability.",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S9",
    "Description": "S9: In a typical month, approximately how many adults (i.e., age 18 or older) do you actively manage care for who have been diagnosed according to the DSM-V criteria with Major Depressive Disorder (MDD)? Please do not include dysthymia or situational depr",
    "Answer_Options": "NA"
  },
  {
    "Column": "S10",
    "Description": "S10: Of the adult patients with MDD you see in a typical month, approximately how many have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive episode?",
    "Answer_Options": "NA"
  },
  {
    "Column": "S11",
    "Description": "S11: Do you personally make treatment decisions for patients who have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive episode?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S12r1",
    "Description": "S12r1: Selective serotonin reuptake inhibitors (SSRIs) (e.g., Prozac, Zoloft, Celexa, etc.) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequ",
    "Answer_Options": "0=NO TO: Selective serotonin reuptake inhibitors (SSRIs) (e.g., Prozac, Zoloft, Celexa, etc.),1=Selective serotonin reuptake inhibitors (SSRIs) (e.g., Prozac, Zoloft, Celexa, etc.)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r2",
    "Description": "S12r2: Serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., Cymbalta, Effexor, Pristiq, etc.) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experi",
    "Answer_Options": "0=NO TO: Serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., Cymbalta, Effexor, Pristiq, etc.),1=Serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., Cymbalta, Effexor, Pristiq, etc.)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r3",
    "Description": "S12r3: Dopaminergic/noradrenergic agents - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressants of",
    "Answer_Options": "0=NO TO: Dopaminergic/noradrenergic agents,1=Dopaminergic/noradrenergic agents",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r4",
    "Description": "S12r4: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral",
    "Answer_Options": "0=NO TO: Trintellix (vortioxetine) and/or Viibryd (vilazodone),1=Trintellix (vortioxetine) and/or Viibryd (vilazodone)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r5",
    "Description": "S12r5: Wellbutrin (bupropion) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressants of adequate do",
    "Answer_Options": "0=NO TO: Wellbutrin (bupropion),1=Wellbutrin (bupropion)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r6",
    "Description": "S12r6: Atypical antipsychotics (e.g., Vraylar, Rexulti) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral anti",
    "Answer_Options": "0=NO TO: Atypical antipsychotics (e.g., Vraylar, Rexulti),1=Atypical antipsychotics (e.g., Vraylar, Rexulti)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r7",
    "Description": "S12r7: Auvelity (dextromethorphan – bupropion) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepress",
    "Answer_Options": "0=NO TO: Auvelity (dextromethorphan – bupropion),1=Auvelity (dextromethorphan – bupropion)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r8",
    "Description": "S12r8: Spravato (esketamine) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dos",
    "Answer_Options": "0=NO TO: Spravato (esketamine),1=Spravato (esketamine)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r9",
    "Description": "S12r9: IV Ketamine - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and dura",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r10",
    "Description": "S12r10: Transcranial Magnetic Stimulation (TMS) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressa",
    "Answer_Options": "0=NO TO: Transcranial Magnetic Stimulation (TMS),1=Transcranial Magnetic Stimulation (TMS)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r11",
    "Description": "S12r11: Electroconvulsive Therapy (ECT) - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressants of a",
    "Answer_Options": "0=NO TO: Electroconvulsive Therapy (ECT),1=Electroconvulsive Therapy (ECT)",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r12",
    "Description": "S12r12: None of the above - In the past 12 months, which, if any, of the following types of medication have you prescribed or made a referral for your patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose a",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "S12"
  },
  {
    "Column": "HV_SPRAVATO",
    "Description": "HV_SPRAVATO: SPRAVATO RESPONDENT TYPE",
    "Answer_Options": "1=NON-TREAT / NON-REFER,2=TREATER OR REFERRER"
  },
  {
    "Column": "S13r1c1",
    "Description": "S13r1c1: Patients you personally treated with this - Spravato - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive epi",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r1c2",
    "Description": "S13r1c2: Patients you refer to another provider in your practice to treat - Spravato - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r1c3",
    "Description": "S13r1c3: Patients you refer to another provider outside your practice to treat - Spravato - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration withi",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r2c1",
    "Description": "S13r2c1: Patients you personally treated with this - IV ketamine - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r2c2",
    "Description": "S13r2c2: Patients you refer to another provider in your practice to treat - IV ketamine - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r2c3",
    "Description": "S13r2c3: Patients you refer to another provider outside your practice to treat - IV ketamine - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration wi",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r3c1",
    "Description": "S13r3c1: Patients you personally treated with this - Transcranial Magnetic Stimulation (TMS) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration wi",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r3c2",
    "Description": "S13r3c2: Patients you refer to another provider in your practice to treat - Transcranial Magnetic Stimulation (TMS) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequa",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r3c3",
    "Description": "S13r3c3: Patients you refer to another provider outside your practice to treat - Transcranial Magnetic Stimulation (TMS) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of a",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r4c1",
    "Description": "S13r4c1: Patients you personally treated with this - Electroconvulsive therapy (ECT) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r4c2",
    "Description": "S13r4c2: Patients you refer to another provider in your practice to treat - Electroconvulsive therapy (ECT) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate dose",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r4c3",
    "Description": "S13r4c3: Patients you refer to another provider outside your practice to treat - Electroconvulsive therapy (ECT) - In the past 12 months, for how many adult patients that have experienced inadequate response to at least 2 oral antidepressants of adequate",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "HV_SPRAVATO_S13",
    "Description": "HV_SPRAVATO_S13: HIDDEN VARIABLES FOR BOTH SPRAVATO",
    "Answer_Options": "1=TREATER,2=REFERRER,3=NON-TREAT / NON-REFER: NEITHER OF THE ABOVE,4=TREATER AND REFERRER"
  },
  {
    "Column": "h13Sum1",
    "Description": "h13Sum1: Product Referral Sum: Spravato",
    "Answer_Options": "NA"
  },
  {
    "Column": "h13Sum2",
    "Description": "h13Sum2: Product Referral Sum: IV ketamine",
    "Answer_Options": "NA"
  },
  {
    "Column": "h13Sum3",
    "Description": "h13Sum3: Product Referral Sum: Transcranial Magnetic Stimulation (TMS)",
    "Answer_Options": "NA"
  },
  {
    "Column": "h13Sum4",
    "Description": "h13Sum4: Product Referral Sum: Electroconvulsive therapy (ECT)",
    "Answer_Options": "NA"
  },
  {
    "Column": "HV_SPRAVATO_S13_QUOTA",
    "Description": "HV_SPRAVATO_S13_QUOTA: HIDDEN VARIABLES FOR BOTH SPRAVATO",
    "Answer_Options": "1=TREATER AND REFERRER,2=TREATER ONLY - NOT REFERRER"
  },
  {
    "Column": "S14",
    "Description": "S14: Is your practice REMS-certified for the administration of Spravato?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S15",
    "Description": "S15: We noticed you cited in the past 12 months you prescribed Spravato and that your practice is not REMS-certified for the administration of Spravato. Please confirm below if that is correct.",
    "Answer_Options": "1=Yes, I have prescribed Spravato and my practice is not REMS-certified for Spravato,2=No, I’d like to adjust my previous responses"
  },
  {
    "Column": "A1",
    "Description": "A1: [pipe:A1Pipe]",
    "Answer_Options": "1=Less than 1 month,2=1-2 months,3=3-4 months,4=5-6 months,5=More than 6 months,6=I’m not accepting new patients,7=Don’t know or don’t refer enough to Psychiatrists to know"
  },
  {
    "Column": "B12r1",
    "Description": "B12r1: For the remainder of this survey, we are going to focus on treatment-resistant depression, which we’ll abbreviate as TRD. Using the slide below, how much do you agree with the definition below of treatment-resistant depression (TRD)? Treatment-Re",
    "Answer_Options": "NA",
    "ParentQuestion": "B12"
  },
  {
    "Column": "B13",
    "Description": "B13: At what line of treatment would you define a patient as having TRD?",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later"
  },
  {
    "Column": "A2",
    "Description": "A2: Approximately what proportion of your TRD visits are conducted via tele-health (remotely, by Zoom, etc.) as opposed to in person?",
    "Answer_Options": "NA"
  },
  {
    "Column": "A3r1c1",
    "Description": "A3r1c1: A new appointment - When I see patients in-person - Approximately how long do you spend with your TRD patients during each appointment type?",
    "Answer_Options": "1=less than 5 minutes,2=5-9 minutes,3=10-14 minutes,4=15-19 minutes,5=20-24 minutes,6=25-29 minutes,7=30-34 minutes,8=35-39 minutes,9=40-44 minutes,10=45-49 minutes,11=50-54 minutes,12=55-59 minutes,13=60 minutes,14=greater than 60 minutes",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r2c1",
    "Description": "A3r2c1: A follow-up appointment - When I see patients in-person - Approximately how long do you spend with your TRD patients during each appointment type?",
    "Answer_Options": "1=less than 5 minutes,2=5-9 minutes,3=10-14 minutes,4=15-19 minutes,5=20-24 minutes,6=25-29 minutes,7=30-34 minutes,8=35-39 minutes,9=40-44 minutes,10=45-49 minutes,11=50-54 minutes,12=55-59 minutes,13=60 minutes,14=greater than 60 minutes",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r1c2",
    "Description": "A3r1c2: A new appointment - When I see patients via tele-health - Approximately how long do you spend with your TRD patients during each appointment type?",
    "Answer_Options": "1=less than 5 minutes,2=5-9 minutes,3=10-14 minutes,4=15-19 minutes,5=20-24 minutes,6=25-29 minutes,7=30-34 minutes,8=35-39 minutes,9=40-44 minutes,10=45-49 minutes,11=50-54 minutes,12=55-59 minutes,13=60 minutes,14=greater than 60 minutes",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r2c2",
    "Description": "A3r2c2: A follow-up appointment - When I see patients via tele-health - Approximately how long do you spend with your TRD patients during each appointment type?",
    "Answer_Options": "1=less than 5 minutes,2=5-9 minutes,3=10-14 minutes,4=15-19 minutes,5=20-24 minutes,6=25-29 minutes,7=30-34 minutes,8=35-39 minutes,9=40-44 minutes,10=45-49 minutes,11=50-54 minutes,12=55-59 minutes,13=60 minutes,14=greater than 60 minutes",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3DKr99c1",
    "Description": "A3DKr99c1: When I see patients in-person - A3DK",
    "Answer_Options": "0=NO TO: When I see patients in-person,1=When I see patients in-person",
    "ParentQuestion": "A3DK"
  },
  {
    "Column": "A3DKr99c2",
    "Description": "A3DKr99c2: When I see patients via tele-health - A3DK",
    "Answer_Options": "0=NO TO: When I see patients via tele-health,1=When I see patients via tele-health",
    "ParentQuestion": "A3DK"
  },
  {
    "Column": "A4r1",
    "Description": "A4r1: How many times per year, on average, do you see your typical TRD patients?",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A5r1",
    "Description": "A5r1: Those patients to transition from first-line treatment to second-line treatment - For the following question, please review the following definition: A new line of therapy is defined as: Adding a new treatment to an existing regiment A complete chan",
    "Answer_Options": "1=1 month,2=2 months,3=3 months,4=4 months,5=5 months,6=6 months,7=7 months,8=8 months,9=9 months,10=10 months,11=11 months,12=12 months,13=13 months,14=14 months,15=15 months,16=16 months,17=17 months,18=18 months,19=19 months,20=20 months,21=21 months,22=22 months,23=23 months,24=24 months,25=25 months,26=26 months,27=27 months,28=28 months,29=29 months,30=30 months,31=31 months,32=32 months,33=33 months,34=34 months,35=35 months,36=36 months,37=37 months,38=38 months,39=39 months,40=40 months,41=41 months,42=42 months,43=43 months,44=44 months,45=45 months,46=46 months,47=47 months,48=48 months,49=49 months,50=50 months,51=51 months,52=52 months,53=53 months,54=54 months,55=55 months,56=56 months,57=57 months,58=58 months,59=59 months,60=60 months,61=greater than 60 months,62=These patients never transition to this line of treatment",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r2",
    "Description": "A5r2: Those patients to transition from second-line treatment to third-line treatment - For the following question, please review the following definition: A new line of therapy is defined as: Adding a new treatment to an existing regiment A complete chan",
    "Answer_Options": "1=1 month,2=2 months,3=3 months,4=4 months,5=5 months,6=6 months,7=7 months,8=8 months,9=9 months,10=10 months,11=11 months,12=12 months,13=13 months,14=14 months,15=15 months,16=16 months,17=17 months,18=18 months,19=19 months,20=20 months,21=21 months,22=22 months,23=23 months,24=24 months,25=25 months,26=26 months,27=27 months,28=28 months,29=29 months,30=30 months,31=31 months,32=32 months,33=33 months,34=34 months,35=35 months,36=36 months,37=37 months,38=38 months,39=39 months,40=40 months,41=41 months,42=42 months,43=43 months,44=44 months,45=45 months,46=46 months,47=47 months,48=48 months,49=49 months,50=50 months,51=51 months,52=52 months,53=53 months,54=54 months,55=55 months,56=56 months,57=57 months,58=58 months,59=59 months,60=60 months,61=greater than 60 months,62=These patients never transition to this line of treatment",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A6r1",
    "Description": "A6r1: Patients experience partial response on SSRI / SNRI, with no safety / tolerability concerns - For each scenario, please indicate what action you would most likely take as a result when treating TRD. Please assume the patients have already been titra",
    "Answer_Options": "1=I am likely to add on an additional treatment(s),2=I am likely to switch to another treatment(s),3=I am likely to refer to another physician,4=I am not likely to take any of these actions at this time",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r2",
    "Description": "A6r2: Patients experience partial response on atypical anti-psychotics, with no safety / tolerability concerns - For each scenario, please indicate what action you would most likely take as a result when treating TRD. Please assume the patients have alrea",
    "Answer_Options": "1=I am likely to add on an additional treatment(s),2=I am likely to switch to another treatment(s),3=I am likely to refer to another physician,4=I am not likely to take any of these actions at this time",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r3",
    "Description": "A6r3: Patients experience no response on SSRI / SNRI, with no safety / tolerability concerns - For each scenario, please indicate what action you would most likely take as a result when treating TRD. Please assume the patients have already been titrated t",
    "Answer_Options": "1=I am likely to add on an additional treatment(s),2=I am likely to switch to another treatment(s),3=I am likely to refer to another physician,4=I am not likely to take any of these actions at this time",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r4",
    "Description": "A6r4: Patients experience no response on atypical anti-psychotics, with no safety / tolerability concerns - For each scenario, please indicate what action you would most likely take as a result when treating TRD. Please assume the patients have already be",
    "Answer_Options": "1=I am likely to add on an additional treatment(s),2=I am likely to switch to another treatment(s),3=I am likely to refer to another physician,4=I am not likely to take any of these actions at this time",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r5",
    "Description": "A6r5: Patients experience at least partial response with side effects (e.g. weight loss, sexual disfunction, etc.) on SSRI / SNRI - For each scenario, please indicate what action you would most likely take as a result when treating TRD. Please assume the",
    "Answer_Options": "1=I am likely to add on an additional treatment(s),2=I am likely to switch to another treatment(s),3=I am likely to refer to another physician,4=I am not likely to take any of these actions at this time",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r6",
    "Description": "A6r6: Patients experience at least partial response with side effects (e.g. weight loss, sexual disfunction, etc.) on atypical anti-psychotics - For each scenario, please indicate what action you would most likely take as a result when treating TRD. Pleas",
    "Answer_Options": "1=I am likely to add on an additional treatment(s),2=I am likely to switch to another treatment(s),3=I am likely to refer to another physician,4=I am not likely to take any of these actions at this time",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A7r1",
    "Description": "A7r1: I wish I could spend more time with my TRD patients - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r2",
    "Description": "A7r2: Educating TRD patients on the condition & treatment is an important part of my role - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r3",
    "Description": "A7r3: If I refer a TRD patient to another physician for interventional therapy, I fear that I may “lose” the patient - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r4",
    "Description": "A7r4: I coordinate treatment with my TRD patients’ other providers as much as possible - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r5",
    "Description": "A7r5: I treat and assess my TRD patients differently than my MDD patients - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r6",
    "Description": "A7r6: I collaborate with my patients when making treatment decisions - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A8",
    "Description": "A8: What is the earliest point at which you typically refer TRD patients to other physicians for further treatment such as interventional therapy? Reminder: TRD patients are in third line or later.",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I never or very rarely refer these patients at any line of treatment"
  },
  {
    "Column": "A9r1",
    "Description": "A9r1: When I think the patient is misdiagnosed (diagnosis is other than MDD) - Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment?",
    "Answer_Options": "0=NO TO: When I think the patient is misdiagnosed (diagnosis is other than MDD),1=When I think the patient is misdiagnosed (diagnosis is other than MDD)",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9r2",
    "Description": "A9r2: When I feel the patient’s condition falls outside of my expertise - Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment?",
    "Answer_Options": "0=NO TO: When I feel the patient’s condition falls outside of my expertise,1=When I feel the patient’s condition falls outside of my expertise",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9r3",
    "Description": "A9r3: When my patient asks to be referred - Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment?",
    "Answer_Options": "0=NO TO: When my patient asks to be referred,1=When my patient asks to be referred",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9r4",
    "Description": "A9r4: When I think there’s another appropriate treatment I am not currently using - Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment?",
    "Answer_Options": "0=NO TO: When I think there’s another appropriate treatment I am not currently using,1=When I think there’s another appropriate treatment I am not currently using",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9r6",
    "Description": "A9r6: Other (please specify) - Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment?",
    "Answer_Options": "0=NO TO: Other (please specify),1=Other (please specify)",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9r5",
    "Description": "A9r5: I never refer MDD / TRD patients to other physicians - Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment?",
    "Answer_Options": "0=NO TO: I never refer MDD / TRD patients to other physicians,1=I never refer MDD / TRD patients to other physicians",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9r6oe",
    "Description": "A9r6oe: Which of the following describes the reasons you refer MDD / TRD patients to other physicians for further treatment? - Other (please specify)",
    "Answer_Options": "NA",
    "ParentQuestion": "A9"
  },
  {
    "Column": "dummyB1Rand",
    "Description": "dummyB1Rand: DUMMY B1 RANDOMIZATION",
    "Answer_Options": "1=Straight,2=Reverse"
  },
  {
    "Column": "dummyB1ROT",
    "Description": "dummyB1ROT: dummyB1ROT",
    "Answer_Options": "1=Colleagues seek my advice for treating TRD,2=I seek advice from colleagues for treating TRD,3=When treating TRD, I reach for the tried-and-true options,4=When treating TRD, I reach for the new and innovative options whenever possible,5=When treating TRD, I have a standardized treatment algorithm I developed to manage my patients with TRD,6=When treating TRD, I prefer to customize treatment based on my understanding of the patient’s needs,7=When prescribing for TRD, I present treatment options with pros and cons to my patients and include them in the decision,8=When prescribing for TRD, I select and advocate for the best treatment option to my patients,9=If my TRD patients request a particular treatment, I grant their request whenever possible,10=If my TRD patients request a particular treatment, it rarely influences my decision-making,11=In TRD, I prefer prescribing the minimal number of medications possible for each patient,12=In TRD, I prefer prescribing the most effective treatment regimen possible regardless of the number of medications it in,13=I view starting a new treatment as a benefit – an opportunity to try something new,14=I view starting a new treatment as a disappointment – a recognition that their current treatment isn’t working,15=If a given treatment for TRD isn’t providing an adequate response, I am inclined to switch to another treatment,16=If a given treatment for TRD isn’t providing an adequate response, I am inclined to add on another treatment,17=In treatment of TRD, I will try multiple oral treatments in the same class (e.g., SSRIs, SNRIs) before introducing anoth,18=In treatment of TRD, I am quick to move onto the next class of medication without trying multiple oral treatments in the,19=My progression of treatment choices for TRD patients moving into later lines of treatment is largely the same across pat,20=My progression of treatment choices for TRD patients moving into later lines of treatment is largely different for each,21=Maximizing efficacy is my priority when treating TRD patients,22=Minimizing side effects is my priority when treating TRD patients,23=My TRD patients view starting a new treatment as a benefit – an opportunity to try something new,24=My TRD patients view starting a new treatment as a disappointment – a recognition that their current treatment isn’t"
  },
  {
    "Column": "B1r1",
    "Description": "B1r1: Colleagues seek my advice for treating TRD / I seek advice from colleagues for treating TRD - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r2",
    "Description": "B1r2: When treating TRD, I reach for the tried-and-true options / When treating TRD, I reach for the new and innovative options whenever possible - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r3",
    "Description": "B1r3: When treating TRD, I have a standardized treatment algorithm I developed to manage my patients with TRD / When treating TRD, I prefer to customize treatment based on my understanding of the patient’s needs - For each pair of statements, please sel",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r4",
    "Description": "B1r4: When prescribing for TRD, I present treatment options with pros and cons to my patients and include them in the decision / When prescribing for TRD, I select and advocate for the best treatment option to my patients - For each pair of statements, pl",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r5",
    "Description": "B1r5: If my TRD patients request a particular treatment, I grant their request whenever possible / If my TRD patients request a particular treatment, it rarely influences my decision-making - For each pair of statements, please select the one you most ide",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r6",
    "Description": "B1r6: In TRD, I prefer prescribing the minimal number of medications possible for each patient / In TRD, I prefer prescribing the most effective treatment regimen possible regardless of the number of medications it involves - For each pair of statements,",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r7",
    "Description": "B1r7: I view starting a new treatment as a benefit – an opportunity to try something new / I view starting a new treatment as a disappointment – a recognition that their current treatment isn’t working - For each pair of statements, please select th",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r8",
    "Description": "B1r8: If a given treatment for TRD isn’t providing an adequate response, I am inclined to switch to another treatment / If a given treatment for TRD isn’t providing an adequate response, I am inclined to add on another treatment - For each pair of sta",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r9",
    "Description": "B1r9: In treatment of TRD, I will try multiple oral treatments in the same class (e.g., SSRIs, SNRIs) before introducing another class of medication / In treatment of TRD, I am quick to move onto the next class of medication without trying multiple oral t",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r11",
    "Description": "B1r11: Maximizing efficacy is my priority when treating TRD patients / Minimizing side effects is my priority when treating TRD patients - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r12",
    "Description": "B1r12: My TRD patients view starting a new treatment as a benefit – an opportunity to try something new / My TRD patients view starting a new treatment as a disappointment – a recognition that their current treatment isn’t working - For each pair of",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B2r1",
    "Description": "B2r1: Even if the initial few treatments do not provide adequate response for a TRD patient, I remain optimistic about eventually finding the right approach - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r2",
    "Description": "B2r2: Patient disappointment over inadequate response to initial treatment prevents me from being able to move them along in the treatment process as quickly as I’d like - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r3",
    "Description": "B2r3: There is a strong need for more medication options for TRD patients - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r4",
    "Description": "B2r4: I’m hesitant to prescribe newer treatment options for TRD patients - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r5",
    "Description": "B2r5: I like to stick with the tried-and-true treatments for TRD patients - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r6",
    "Description": "B2r6: I consider myself innovative when it comes to treating TRD patients - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r7",
    "Description": "B2r7: I prefer options such as Spravato, TMS, ECT and/or IV Ketamine because they ensure patients receive the treatment - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r8",
    "Description": "B2r8: I believe TRD patients prefer pills over non oral administration - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r9",
    "Description": "B2r9: A product with a monotherapy indication offers great value when treating TRD - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B2r10",
    "Description": "B2r10: I would introduce an interventional treatment earlier in my treatment algorithm if I believed it would give my patients relief of their depressive symptoms - How much do you agree with the following statements?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "B2"
  },
  {
    "Column": "B3r1",
    "Description": "B3r1: Treatments with rapid efficacy - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Treatments with rapid efficacy,1=Treatments with rapid efficacy",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r2",
    "Description": "B3r2: Treatments with sustained efficacy - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Treatments with sustained efficacy,1=Treatments with sustained efficacy",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r3",
    "Description": "B3r3: Patients’ preferences regarding route of administration - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Patients’ preferences regarding route of administration,1=Patients’ preferences regarding route of administration",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r4",
    "Description": "B3r4: Ease of use for you / your practice in administering a treatment - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Ease of use for you / your practice in administering a treatment,1=Ease of use for you / your practice in administering a treatment",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r5",
    "Description": "B3r5: Ease of administration for patients - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Ease of administration for patients,1=Ease of administration for patients",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r6",
    "Description": "B3r6: Favorable dosing frequency - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Favorable dosing frequency,1=Favorable dosing frequency",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r7",
    "Description": "B3r7: Treatments that are non-addictive - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Treatments that are non-addictive,1=Treatments that are non-addictive",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r8",
    "Description": "B3r8: Treatments with a favorable safety or side effect profile - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Treatments with a favorable safety or side effect profile,1=Treatments with a favorable safety or side effect profile",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r9",
    "Description": "B3r9: Not a controlled substance - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Not a controlled substance,1=Not a controlled substance",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r10",
    "Description": "B3r10: No requirement to participate in REMS - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: No requirement to participate in REMS,1=No requirement to participate in REMS",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r11",
    "Description": "B3r11: Whether you’ve had personal success with this treatment in the past - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Whether you’ve had personal success with this treatment in the past,1=Whether you’ve had personal success with this treatment in the past",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r12",
    "Description": "B3r12: Whether a treatment is indicated for use in either monotherapy or in combination therapy - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Whether a treatment is indicated for use in either monotherapy or in combination therapy,1=Whether a treatment is indicated for use in either monotherapy or in combination therapy",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r13",
    "Description": "B3r13: Positive financial impact on your practice - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Positive financial impact on your practice,1=Positive financial impact on your practice",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r14",
    "Description": "B3r14: Lower out-of-pocket cost to your patients - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Lower out-of-pocket cost to your patients,1=Lower out-of-pocket cost to your patients",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r15",
    "Description": "B3r15: Ease of getting treatment(s) approved by insurance plans - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: Ease of getting treatment(s) approved by insurance plans,1=Ease of getting treatment(s) approved by insurance plans",
    "ParentQuestion": "B3"
  },
  {
    "Column": "B3r16",
    "Description": "B3r16: MOA that a patient hasn’t tried before - What factors have the most impact on your treatment decisions when treating patients with TRD?",
    "Answer_Options": "0=NO TO: MOA that a patient hasn’t tried before,1=MOA that a patient hasn’t tried before",
    "ParentQuestion": "B3"
  },
  {
    "Column": "hB3Count",
    "Description": "hB3Count: B3: # of items selected",
    "Answer_Options": "NA"
  },
  {
    "Column": "B4r1",
    "Description": "B4r1: Trintellix - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r2",
    "Description": "B4r2: Vraylar - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r3",
    "Description": "B4r3: Rexulti - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r4",
    "Description": "B4r4: Auvelity - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r5",
    "Description": "B4r5: Spravato - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r6",
    "Description": "B4r6: IV Ketamine - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r7",
    "Description": "B4r7: Transcranial Magnetic Stimulation (TMS) - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B4r8",
    "Description": "B4r8: Electroconvulsive Therapy (ECT) - Which of the following best describes your familiarity with and use of the following treatments?",
    "Answer_Options": "1=Never heard of it,2=Know of it, but have never prescribed nor referred patients for this treatment myself,3=Know of it and have prescribed this treatment myself at least once in the past,4=Know of it and have referred patients for this treatment at least once in the past",
    "ParentQuestion": "B4"
  },
  {
    "Column": "B5r1",
    "Description": "B5r1: Trintellix - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r2",
    "Description": "B5r2: Vraylar - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r3",
    "Description": "B5r3: Rexulti - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r4",
    "Description": "B5r4: Auvelity - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r5",
    "Description": "B5r5: Spravato - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r6",
    "Description": "B5r6: IV Ketamine - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r7",
    "Description": "B5r7: Transcranial Magnetic Stimulation (TMS) - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r8",
    "Description": "B5r8: Electroconvulsive Therapy (ECT) - What is your overall impression of each of the following treatments?",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B6r1",
    "Description": "B6r1: Selective serotonin reuptake inhibitors (SSRIs) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r2",
    "Description": "B6r2: Serotonin and norepinephrine reuptake inhibitors (SNRIs) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both tr",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r3",
    "Description": "B6r3: Dopaminergic/noradrenergic agents - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r4",
    "Description": "B6r4: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treat",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r5",
    "Description": "B6r5: Wellbutrin (bupropion) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patient",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r6",
    "Description": "B6r6: Atypical antipsychotics (e.g., Vraylar, Rexulti) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r7",
    "Description": "B6r7: Auvelity (dextromethorphan – bupropion) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and re",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r8",
    "Description": "B6r8: Spravato (esketamine) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r9",
    "Description": "B6r9: IV Ketamine - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients under you",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r10",
    "Description": "B6r10: Transcranial Magnetic Stimulation (TMS) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and ref",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r11",
    "Description": "B6r11: Electroconvulsive Therapy (ECT) - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals f",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "B6r13",
    "Description": "B6r13: Other - Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients under your car",
    "Answer_Options": "NA",
    "ParentQuestion": "B6"
  },
  {
    "Column": "noanswerB6_r12",
    "Description": "noanswerB6_r12: Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are currently being treated with each of the following? Please consider both treatments and referrals for patients under your ca",
    "Answer_Options": "0=NO TO: Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage ar,1=Thinking about your adult TRD patients whom you have personally treated in the past 12 months, what percentage are curre",
    "ParentQuestion": "noanswerB6_"
  },
  {
    "Column": "B6ar1",
    "Description": "B6ar1: Abilify (aripiprazole) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "Answer_Options": "NA",
    "ParentQuestion": "B6a"
  },
  {
    "Column": "B6ar2",
    "Description": "B6ar2: Seroquel (Quetiapine XR/ER) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "Answer_Options": "NA",
    "ParentQuestion": "B6a"
  },
  {
    "Column": "B6ar3",
    "Description": "B6ar3: Rexulti (Brexpiprazole) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "Answer_Options": "NA",
    "ParentQuestion": "B6a"
  },
  {
    "Column": "B6ar4",
    "Description": "B6ar4: Vraylar (cariprazine) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "Answer_Options": "NA",
    "ParentQuestion": "B6a"
  },
  {
    "Column": "B6ar8",
    "Description": "B6ar8: Risperdal (Risperidone) - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "Answer_Options": "NA",
    "ParentQuestion": "B6a"
  },
  {
    "Column": "B6ar7",
    "Description": "B6ar7: Other - Thinking about your TRD patients whom you have personally treated in the past 12 months with atypical antipsychotics, what percentage are currently being treated with each of the following brands?",
    "Answer_Options": "NA",
    "ParentQuestion": "B6a"
  },
  {
    "Column": "B7r1",
    "Description": "B7r1: % who you diagnosed personally or via internal practice referral - Of your Spravato patients, what percent fall into each group below?",
    "Answer_Options": "NA",
    "ParentQuestion": "B7"
  },
  {
    "Column": "B7r2",
    "Description": "B7r2: % who were referred to your care from outside your practice - Of your Spravato patients, what percent fall into each group below?",
    "Answer_Options": "NA",
    "ParentQuestion": "B7"
  },
  {
    "Column": "B8",
    "Description": "B8: Does your office use buy-and-bill to acquire and administer Spravato?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "B9r1",
    "Description": "B9r1: Trintellix - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r2",
    "Description": "B9r2: Vraylar - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r3",
    "Description": "B9r3: Rexulti - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r4",
    "Description": "B9r4: Auvelity - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r5",
    "Description": "B9r5: Spravato - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r6",
    "Description": "B9r6: IV Ketamine - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r7",
    "Description": "B9r7: Transcranial Magnetic Stimulation (TMS) - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B9r8",
    "Description": "B9r8: Electroconvulsive Therapy (ECT) - When in your treatment progression do you typically consider the following?",
    "Answer_Options": "1=First line,2=Second line,3=Third line,4=Fourth line,5=Fifth line,6=Sixth line or later,9=I don’t consider this treatment",
    "ParentQuestion": "B9"
  },
  {
    "Column": "B10r1",
    "Description": "B10r1: Trintellix - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r2",
    "Description": "B10r2: Vraylar - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r3",
    "Description": "B10r3: Rexulti - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r4",
    "Description": "B10r4: Auvelity - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r5",
    "Description": "B10r5: Spravato - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r6",
    "Description": "B10r6: IV Ketamine - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r7",
    "Description": "B10r7: Transcranial Magnetic Stimulation (TMS) - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "B10r8",
    "Description": "B10r8: Electroconvulsive Therapy (ECT) - To what degree, if at all, do you expect your prescribing of or referring for the following to change in the in the next three months?",
    "Answer_Options": "1=Expect prescribing and/or referring to decrease greatly,2=Expect prescribing and/or referring to decrease somewhat,3=Expect prescribing and/or referring to remain the same as today,4=Expect prescribing and/or referring to increase somewhat,5=Expect prescribing and/or referring to increase greatly",
    "ParentQuestion": "B10"
  },
  {
    "Column": "dummyB11Rand",
    "Description": "dummyB11Rand: DUMMY B11 RANDOMIZATION",
    "Answer_Options": "1=Straight,2=Reverse"
  },
  {
    "Column": "dummyB11ROT",
    "Description": "dummyB11ROT: dummyB11ROT",
    "Answer_Options": "1=When a patient is on their third line or later, I think of their condition as “treatment-resistant MDD”,2=When a patient is on their third line or later, I still think of their condition as just “MDD”,3=When assessing medication efficacy in TRD, I rely most on assessment scales (e.g., PHQ-9),4=When assessing medication efficacy in TRD, I rely most on my impression from patient discussion & feedback"
  },
  {
    "Column": "B11r1",
    "Description": "B11r1: When a patient is on their third line or later, I think of their condition as 'treatment-resistant MDD' / When a patient is on their third line or later, I still think of their condition as just 'MDD' - For each pair of statements, please select th",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B11"
  },
  {
    "Column": "B11r2",
    "Description": "B11r2: When assessing medication efficacy in TRD, I rely most on assessment scales (e.g., PHQ-9) / When assessing medication efficacy in TRD, I rely most on my impression from patient discussion & feedback - For each pair of statements, please select the",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "B11"
  },
  {
    "Column": "C2",
    "Description": "C2: What is your overall impression of Spravato now that you’ve seen this product profile?[res Spravato_hyperlink]",
    "Answer_Options": "1=Not at all favorable,2=Slightly favorable,3=Moderately favorable,4=Very favorable,5=Extremely favorable"
  },
  {
    "Column": "C3",
    "Description": "C3: How likely would you be to treat more of your TRD patients with Spravato than you do today?[res Spravato_hyperlink]",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Moderately likely,4=Very likely,5=Extremely likely"
  },
  {
    "Column": "C4",
    "Description": "C4: How likely would you be to refer more patients for Spravato than you do today?[res Spravato_hyperlink]",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Moderately likely,4=Very likely,5=Extremely likely"
  },
  {
    "Column": "C5r1c1",
    "Description": "C5r1c1: Selective serotonin reuptake inhibitors (SSRIs) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Ple",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r2c1",
    "Description": "C5r2c1: Serotonin and norepinephrine reuptake inhibitors (SNRIs) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 mo",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r3c1",
    "Description": "C5r3c1: Dopaminergic/$ {\"\" if gv.request.device.isMobileDevice() else \"\"}noradrenergic agents - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r4c1",
    "Description": "C5r4c1: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 month",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r5c1",
    "Description": "C5r5c1: Wellbutrin (bupropion) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatme",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r6c1",
    "Description": "C5r6c1: Atypical antipsychotics - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatm",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r7c1",
    "Description": "C5r7c1: Auvelity (dextromethorphan – bupropion) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please co",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r8c1",
    "Description": "C5r8c1: Spravato (esketamine) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatmen",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r9c1",
    "Description": "C5r9c1: IV Ketamine - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and ref",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r10c1",
    "Description": "C5r10c1: Transcranial Magnetic Stimulation (TMS) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please con",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r11c1",
    "Description": "C5r11c1: Electroconvulsive Therapy (ECT) - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider bo",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r12c1",
    "Description": "C5r12c1: Other - Current - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and referral",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r1c2",
    "Description": "C5r1c2: Selective serotonin reuptake inhibitors (SSRIs) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 mont",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r2c2",
    "Description": "C5r2c2: Serotonin and norepinephrine reuptake inhibitors (SNRIs) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the nex",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r3c2",
    "Description": "C5r3c2: Dopaminergic/$ {\"\" if gv.request.device.isMobileDevice() else \"\"}noradrenergic agents - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r4c2",
    "Description": "C5r4c2: Trintellix (vortioxetine) and/or Viibryd (vilazodone) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 1",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r5c2",
    "Description": "C5r5c2: Wellbutrin (bupropion) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r6c2",
    "Description": "C5r6c2: Atypical antipsychotics - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r7c2",
    "Description": "C5r7c2: Auvelity (dextromethorphan – bupropion) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Pl",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r8c2",
    "Description": "C5r8c2: Spravato (esketamine) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both t",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r9c2",
    "Description": "C5r9c2: IV Ketamine - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r10c2",
    "Description": "C5r10c2: Transcranial Magnetic Stimulation (TMS) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Ple",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r11c2",
    "Description": "C5r11c2: Electroconvulsive Therapy (ECT) - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please cons",
    "Answer_Options": "NA"
  },
  {
    "Column": "C5r12c2",
    "Description": "C5r12c2: Other - Next 12 Months - Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and r",
    "Answer_Options": "NA"
  },
  {
    "Column": "noanswerC5_r13",
    "Description": "noanswerC5_r13: Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you would recommend each of the following over the next 12 months. Please consider both treatments and referrals.[res Spra",
    "Answer_Options": "0=NO TO: Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you beli,1=Thinking about your adult TRD patients who you personally treat, please indicate the percentage for whom you believe you",
    "ParentQuestion": "noanswerC5_"
  },
  {
    "Column": "hC5_8Spravato",
    "Description": "hC5_8Spravato: C5_8: Change in Spravato – C5_8 minus B6_8",
    "Answer_Options": "NA"
  },
  {
    "Column": "C6r1",
    "Description": "C6r1: Trintellix - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r2",
    "Description": "C6r2: Vraylar - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r3",
    "Description": "C6r3: Rexulti - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r4",
    "Description": "C6r4: Auvelity - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r5",
    "Description": "C6r5: Spravato - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r6",
    "Description": "C6r6: IV Ketamine - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r7",
    "Description": "C6r7: Transcranial Magnetic Stimulation (TMS) - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C6r8",
    "Description": "C6r8: Electroconvulsive Therapy (ECT) - For TRD patients for whom you would consider each of the following treatments over the next 12 months, where in your treatment progression would you consider each?[res Spravato_hyperlink]",
    "Answer_Options": "1=Third line,2=Fourth line,3=Fifth line,4=Sixth line,5=Seventh line or later,6=I wouldn’t consider this treatment",
    "ParentQuestion": "C6"
  },
  {
    "Column": "C7",
    "Description": "C7: For patients for whom you would consider Spravato over the next 12 months, which of the following best describes you?[res Spravato_hyperlink]",
    "Answer_Options": "1=I would expect to treat all my Spravato patients myself and ensure my practice is REMS-certified to administer Spravato,,2=I would expect to refer all my Spravato patients to other physicians,3=I would expect to treat some of my Spravato patients myself and refer some of my Spravato patients to other physicians,4=None of the above apply"
  },
  {
    "Column": "C8r1",
    "Description": "C8r1: Patients show reduction in depressive symptoms when exhibiting suicidal ideation or behavior - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravat",
    "Answer_Options": "0=NO TO: Patients show reduction in depressive symptoms when exhibiting suicidal ideation or behavior,1=Patients show reduction in depressive symptoms when exhibiting suicidal ideation or behavior",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r2",
    "Description": "C8r2: I feel motivated keeping my patients on treatment long-term - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I feel motivated keeping my patients on treatment long-term,1=I feel motivated keeping my patients on treatment long-term",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r3",
    "Description": "C8r3: Provides rapid benefit for patients’ depressive symptoms as early as 24 hours - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Provides rapid benefit for patients’ depressive symptoms as early as 24 hours,1=Provides rapid benefit for patients’ depressive symptoms as early as 24 hours",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r4",
    "Description": "C8r4: Treatment is durable over the long term (i.e., patients are able to maintain remission) - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyp",
    "Answer_Options": "0=NO TO: Treatment is durable over the long term (i.e., patients are able to maintain remission),1=Treatment is durable over the long term (i.e., patients are able to maintain remission)",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r5",
    "Description": "C8r5: Helps patients feel like themselves again - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Helps patients feel like themselves again,1=Helps patients feel like themselves again",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r6",
    "Description": "C8r6: I can easily find or obtain this medication/treatment for my patient - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I can easily find or obtain this medication/treatment for my patient,1=I can easily find or obtain this medication/treatment for my patient",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r7",
    "Description": "C8r7: Ease of patient compliance - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Ease of patient compliance,1=Ease of patient compliance",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r8",
    "Description": "C8r8: Covered by a broad range of commercial and government insurance plans - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Covered by a broad range of commercial and government insurance plans,1=Covered by a broad range of commercial and government insurance plans",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r9",
    "Description": "C8r9: Simple insurance/prior authorization approval - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Simple insurance/prior authorization approval,1=Simple insurance/prior authorization approval",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r10",
    "Description": "C8r10: Flexibility to tailor dosing and frequency based on individual patient need - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Flexibility to tailor dosing and frequency based on individual patient need,1=Flexibility to tailor dosing and frequency based on individual patient need",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r11",
    "Description": "C8r11: Comfort prescribing or referring out for this alone or in combination with another treatment - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Sprava",
    "Answer_Options": "0=NO TO: Comfort prescribing or referring out for this alone or in combination with another treatment,1=Comfort prescribing or referring out for this alone or in combination with another treatment",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r12",
    "Description": "C8r12: Treatment is well tolerated - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Treatment is well tolerated,1=Treatment is well tolerated",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r13",
    "Description": "C8r13: Side effects resolve quickly - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Side effects resolve quickly,1=Side effects resolve quickly",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r14",
    "Description": "C8r14: Limited concern of sexual dysfunction - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Limited concern of sexual dysfunction,1=Limited concern of sexual dysfunction",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r15",
    "Description": "C8r15: Limited concern of weight gain - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Limited concern of weight gain,1=Limited concern of weight gain",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r16",
    "Description": "C8r16: Limited concern of tardive dyskinesia - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Limited concern of tardive dyskinesia,1=Limited concern of tardive dyskinesia",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r17",
    "Description": "C8r17: Unique mechanism of action / treatment modality (nasal spray) - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Unique mechanism of action / treatment modality (nasal spray),1=Unique mechanism of action / treatment modality (nasal spray)",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r18",
    "Description": "C8r18: Requirement to participate in REMS to prescribe Spravato - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Requirement to participate in REMS to prescribe Spravato,1=Requirement to participate in REMS to prescribe Spravato",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r19",
    "Description": "C8r19: Patients benefit from required in-clinic monitoring - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Patients benefit from required in-clinic monitoring,1=Patients benefit from required in-clinic monitoring",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C8r20",
    "Description": "C8r20: Nothing would make me consider prescribing or referring Spravato - How important are each of the following reasons as you think about why you would consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Nothing would make me consider prescribing or referring Spravato,1=Nothing would make me consider prescribing or referring Spravato",
    "ParentQuestion": "C8"
  },
  {
    "Column": "C9r1",
    "Description": "C9r1: Concerns about efficacy - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Concerns about efficacy,1=Concerns about efficacy",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r2",
    "Description": "C9r2: Concerns about safety / side effects - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Concerns about safety / side effects,1=Concerns about safety / side effects",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r3",
    "Description": "C9r3: Concerns about black box warning - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Concerns about black box warning,1=Concerns about black box warning",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r4",
    "Description": "C9r4: Not comfortable using a Schedule III controlled substance and/or a product derived from Ketamine - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res",
    "Answer_Options": "0=NO TO: Not comfortable using a Schedule III controlled substance and/or a product derived from Ketamine,1=Not comfortable using a Schedule III controlled substance and/or a product derived from Ketamine",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r5",
    "Description": "C9r5: Lack of familiarity with the clinical profile of Spravato - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Lack of familiarity with the clinical profile of Spravato,1=Lack of familiarity with the clinical profile of Spravato",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r6",
    "Description": "C9r6: Nasal spray administration - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Nasal spray administration,1=Nasal spray administration",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r7",
    "Description": "C9r7: REMS certification process is cumbersome - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: REMS certification process is cumbersome,1=REMS certification process is cumbersome",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r8",
    "Description": "C9r8: REMS program logistics for the patient to receive each dose - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: REMS program logistics for the patient to receive each dose,1=REMS program logistics for the patient to receive each dose",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r9",
    "Description": "C9r9: REMS program logistics for our practice to administer - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: REMS program logistics for our practice to administer,1=REMS program logistics for our practice to administer",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r10",
    "Description": "C9r10: Uncertainty with insurance coverage or know Spravato is not covered by my patients’ insurance - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res",
    "Answer_Options": "0=NO TO: Uncertainty with insurance coverage or know Spravato is not covered by my patients’ insurance,1=Uncertainty with insurance coverage or know Spravato is not covered by my patients’ insurance",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r11",
    "Description": "C9r11: Patient monitoring services are not covered by insurance - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Patient monitoring services are not covered by insurance,1=Patient monitoring services are not covered by insurance",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r12",
    "Description": "C9r12: Out-of-pocket costs are too high for patients - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Out-of-pocket costs are too high for patients,1=Out-of-pocket costs are too high for patients",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C9r13",
    "Description": "C9r13: Nothing would limit me from considering prescribing or referring Spravato - How important are each of the following reasons as you think about why you would not consider prescribing or referring Spravato when treating TRD?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Nothing would limit me from considering prescribing or referring Spravato,1=Nothing would limit me from considering prescribing or referring Spravato",
    "ParentQuestion": "C9"
  },
  {
    "Column": "C10r1",
    "Description": "C10r1: I don’t know how to identify a patient who is appropriate for Spravato - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I don’t know how to identify a patient who is appropriate for Spravato,1=I don’t know how to identify a patient who is appropriate for Spravato",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r2",
    "Description": "C10r2: My practice isn’t REMS-certified for Spravato - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: My practice isn’t REMS-certified for Spravato,1=My practice isn’t REMS-certified for Spravato",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r3",
    "Description": "C10r3: I’m unwilling to get my practice REMS-certified for Spravato - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I’m unwilling to get my practice REMS-certified for Spravato,1=I’m unwilling to get my practice REMS-certified for Spravato",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r4",
    "Description": "C10r4: My practice lacks staff for Spravato administration and monitoring - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: My practice lacks staff for Spravato administration and monitoring,1=My practice lacks staff for Spravato administration and monitoring",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r5",
    "Description": "C10r5: My practice lacks physical space for Spravato administration and monitoring - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: My practice lacks physical space for Spravato administration and monitoring,1=My practice lacks physical space for Spravato administration and monitoring",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r6",
    "Description": "C10r6: I don’t see enough patients to justify using Spravato myself - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I don’t see enough patients to justify using Spravato myself,1=I don’t see enough patients to justify using Spravato myself",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r7",
    "Description": "C10r7: I don’t have a pharmacy that can distribute Spravato to my location - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I don’t have a pharmacy that can distribute Spravato to my location,1=I don’t have a pharmacy that can distribute Spravato to my location",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r8",
    "Description": "C10r8: The Prior Authorization process and approval is too time consuming for my practice - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: The Prior Authorization process and approval is too time consuming for my practice,1=The Prior Authorization process and approval is too time consuming for my practice",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r9",
    "Description": "C10r9: Reimbursement for services associated with Spravato administration is insufficient - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Reimbursement for services associated with Spravato administration is insufficient,1=Reimbursement for services associated with Spravato administration is insufficient",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r10",
    "Description": "C10r10: Other - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Other,1=Other",
    "ParentQuestion": "C10"
  },
  {
    "Column": "C10r11",
    "Description": "C10r11: None of the above - Which of the following are barriers that may limit you personally prescribing Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: None of the above,1=None of the above",
    "ParentQuestion": "C10"
  },
  {
    "Column": "hC10Count",
    "Description": "hC10Count: C10: # of items selected",
    "Answer_Options": "NA"
  },
  {
    "Column": "C11r1",
    "Description": "C11r1: I don’t know who to refer patients to - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I don’t know who to refer patients to,1=I don’t know who to refer patients to",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r2",
    "Description": "C11r2: Few / no treatment center(s) within range for my patients - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Few / no treatment center(s) within range for my patients,1=Few / no treatment center(s) within range for my patients",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r3",
    "Description": "C11r3: Treatment centers are within range but not accepting new patients - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Treatment centers are within range but not accepting new patients,1=Treatment centers are within range but not accepting new patients",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r4",
    "Description": "C11r4: Treatment centers are accepting new patients but the wait time is too long - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Treatment centers are accepting new patients but the wait time is too long,1=Treatment centers are accepting new patients but the wait time is too long",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r5",
    "Description": "C11r5: I’m concerned about losing visibility into my patients’ treatment management if I refer - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I’m concerned about losing visibility into my patients’ treatment management if I refer,1=I’m concerned about losing visibility into my patients’ treatment management if I refer",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r6",
    "Description": "C11r6: Treatment centers do not accept my patients’ insurance - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Treatment centers do not accept my patients’ insurance,1=Treatment centers do not accept my patients’ insurance",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r7",
    "Description": "C11r7: I don't know or trust treatment center(s) in my area - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I don't know or trust treatment center(s) in my area,1=I don't know or trust treatment center(s) in my area",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r8",
    "Description": "C11r8: I am unclear on what I need to do to refer my patients to a treatment center - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I am unclear on what I need to do to refer my patients to a treatment center,1=I am unclear on what I need to do to refer my patients to a treatment center",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r9",
    "Description": "C11r9: I am unsatisfied with the communication I receive from treatment centers with updates on my patients’ progress - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I am unsatisfied with the communication I receive from treatment centers with updates on my patients’ progress,1=I am unsatisfied with the communication I receive from treatment centers with updates on my patients’ progress",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r10",
    "Description": "C11r10: Other (please specify) - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: Other (please specify),1=Other (please specify)",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r11",
    "Description": "C11r11: I don’t refer patients for Spravato because I prescribe Spravato myself - Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I don’t refer patients for Spravato because I prescribe Spravato myself,1=I don’t refer patients for Spravato because I prescribe Spravato myself",
    "ParentQuestion": "C11"
  },
  {
    "Column": "C11r10oe",
    "Description": "C11r10oe: Which of the following are barriers that may limit you referring patients for Spravato?[res Spravato_hyperlink] - Other (please specify)",
    "Answer_Options": "NA"
  },
  {
    "Column": "hC11Count",
    "Description": "hC11Count: C11: # of items selected",
    "Answer_Options": "NA"
  },
  {
    "Column": "C12",
    "Description": "C12: Please think about the MDD patients who have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive episode for whom you have referred for Spravato. To the best of your knowledge",
    "Answer_Options": "NA"
  },
  {
    "Column": "noanswerC12_r99",
    "Description": "noanswerC12_r99: Please think about the MDD patients who have experienced inadequate response to at least 2 oral antidepressants of adequate dose and duration within the current depressive episode for whom you have referred for Spravato. To the best of yo",
    "Answer_Options": "0=NO TO: Please think about the MDD patients who have experienced inadequate response to at least 2 oral antidepressants o,1=Please think about the MDD patients who have experienced inadequate response to at least 2 oral antidepressants of adequ",
    "ParentQuestion": "noanswerC12_"
  },
  {
    "Column": "C13",
    "Description": "C13: How likely is it that your practice will become a REMS-certified treatment center for Spravato in the next 12 months?[res Spravato_hyperlink]",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Moderately likely,4=Very likely,5=Extremely likely"
  },
  {
    "Column": "C14",
    "Description": "C14: How knowledgeable are you regarding the process for your practice to become REMS-certified for Spravato?[res Spravato_hyperlink]",
    "Answer_Options": "1=Not at all knowledgeable,2=Slightly knowledgeable,3=Moderately knowledgeable,4=Very knowledgeable,5=Extremely knowledgeable"
  },
  {
    "Column": "C15r1c1",
    "Description": "C15r1c1: Trintellix - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r1c2",
    "Description": "C15r1c2: Vraylar - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that an",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r1c3",
    "Description": "C15r1c3: Rexulti - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that an",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r1c4",
    "Description": "C15r1c4: Auvelity - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that a",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r1c5",
    "Description": "C15r1c5: Spravato - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that a",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r1c6",
    "Description": "C15r1c6: IV Ketamine - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select tha",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r1c7",
    "Description": "C15r1c7: TMS - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r1c8",
    "Description": "C15r1c8: ECT - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r1c9",
    "Description": "C15r1c9: All treatments equally - Clinical efficacy - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r2c1",
    "Description": "C15r2c1: Trintellix - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answ",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r2c2",
    "Description": "C15r2c2: Vraylar - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r2c3",
    "Description": "C15r2c3: Rexulti - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r2c4",
    "Description": "C15r2c4: Auvelity - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r2c5",
    "Description": "C15r2c5: Spravato - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r2c6",
    "Description": "C15r2c6: IV Ketamine - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that ans",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r2c7",
    "Description": "C15r2c7: TMS - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer choi",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r2c8",
    "Description": "C15r2c8: ECT - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answer choi",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r2c9",
    "Description": "C15r2c9: All treatments equally - Rapid effect - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please sele",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r3c1",
    "Description": "C15r3c1: Trintellix - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r3c2",
    "Description": "C15r3c2: Vraylar - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select tha",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r3c3",
    "Description": "C15r3c3: Rexulti - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select tha",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r3c4",
    "Description": "C15r3c4: Auvelity - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select th",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r3c5",
    "Description": "C15r3c5: Spravato - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select th",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r3c6",
    "Description": "C15r3c6: IV Ketamine - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r3c7",
    "Description": "C15r3c7: TMS - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that an",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r3c8",
    "Description": "C15r3c8: ECT - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that an",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r3c9",
    "Description": "C15r3c9: All treatments equally - Fewer safety concerns - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, pl",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r4c1",
    "Description": "C15r4c1: Trintellix - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r4c2",
    "Description": "C15r4c2: Vraylar - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select th",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r4c3",
    "Description": "C15r4c3: Rexulti - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select th",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r4c4",
    "Description": "C15r4c4: Auvelity - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select t",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r4c5",
    "Description": "C15r4c5: Spravato - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select t",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r4c6",
    "Description": "C15r4c6: IV Ketamine - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please selec",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r4c7",
    "Description": "C15r4c7: TMS - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that a",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r4c8",
    "Description": "C15r4c8: ECT - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that a",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r4c9",
    "Description": "C15r4c9: All treatments equally - Long-term tolerability - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, p",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r5c1",
    "Description": "C15r5c1: Trintellix - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatm",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r5c2",
    "Description": "C15r5c2: Vraylar - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatment",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r5c3",
    "Description": "C15r5c3: Rexulti - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatment",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r5c4",
    "Description": "C15r5c4: Auvelity - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatmen",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r5c5",
    "Description": "C15r5c5: Spravato - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatmen",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r5c6",
    "Description": "C15r5c6: IV Ketamine - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treat",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r5c7",
    "Description": "C15r5c7: TMS - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments ar",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r5c8",
    "Description": "C15r5c8: ECT - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments ar",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r5c9",
    "Description": "C15r5c9: All treatments equally - Enables patients to function in everyday life activities - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. I",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r6c1",
    "Description": "C15r6c1: Trintellix - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please sel",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r6c2",
    "Description": "C15r6c2: Vraylar - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r6c3",
    "Description": "C15r6c3: Rexulti - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r6c4",
    "Description": "C15r6c4: Auvelity - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please selec",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r6c5",
    "Description": "C15r6c5: Spravato - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please selec",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r6c6",
    "Description": "C15r6c6: IV Ketamine - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please se",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r6c7",
    "Description": "C15r6c7: TMS - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select tha",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r6c8",
    "Description": "C15r6c8: ECT - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select tha",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r6c9",
    "Description": "C15r6c9: All treatments equally - Easier dosing / frequency - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r7c1",
    "Description": "C15r7c1: Trintellix - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments a",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r7c2",
    "Description": "C15r7c2: Vraylar - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r7c3",
    "Description": "C15r7c3: Rexulti - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r7c4",
    "Description": "C15r7c4: Auvelity - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r7c5",
    "Description": "C15r7c5: Spravato - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r7c6",
    "Description": "C15r7c6: IV Ketamine - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r7c7",
    "Description": "C15r7c7: TMS - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equi",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r7c8",
    "Description": "C15r7c8: ECT - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equi",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r7c9",
    "Description": "C15r7c9: All treatments equally - Easier logistics of administration for the patient - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r8c1",
    "Description": "C15r8c1: Trintellix - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments a",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r8c2",
    "Description": "C15r8c2: Vraylar - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r8c3",
    "Description": "C15r8c3: Rexulti - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r8c4",
    "Description": "C15r8c4: Auvelity - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r8c5",
    "Description": "C15r8c5: Spravato - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r8c6",
    "Description": "C15r8c6: IV Ketamine - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r8c7",
    "Description": "C15r8c7: TMS - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equi",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r8c8",
    "Description": "C15r8c8: ECT - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equi",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r8c9",
    "Description": "C15r8c9: All treatments equally - Easier logistics of administration for my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r9c1",
    "Description": "C15r9c1: Trintellix - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select tha",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r9c2",
    "Description": "C15r9c2: Vraylar - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that a",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r9c3",
    "Description": "C15r9c3: Rexulti - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that a",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r9c4",
    "Description": "C15r9c4: Auvelity - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r9c5",
    "Description": "C15r9c5: Spravato - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r9c6",
    "Description": "C15r9c6: IV Ketamine - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select th",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r9c7",
    "Description": "C15r9c7: TMS - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answe",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r9c8",
    "Description": "C15r9c8: ECT - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select that answe",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r9c9",
    "Description": "C15r9c9: All treatments equally - Patient compliance - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, pleas",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r10c1",
    "Description": "C15r10c1: Trintellix - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please s",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r10c2",
    "Description": "C15r10c2: Vraylar - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please sele",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r10c3",
    "Description": "C15r10c3: Rexulti - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please sele",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r10c4",
    "Description": "C15r10c4: Auvelity - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please sel",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r10c5",
    "Description": "C15r10c5: Spravato - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please sel",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r10c6",
    "Description": "C15r10c6: IV Ketamine - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r10c7",
    "Description": "C15r10c7: TMS - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select t",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r10c8",
    "Description": "C15r10c8: ECT - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please select t",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r10c9",
    "Description": "C15r10c9: All treatments equally - Covered by insurance plans - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivale",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r11c1",
    "Description": "C15r11c1: Trintellix - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are e",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r11c2",
    "Description": "C15r11c2: Vraylar - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equi",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r11c3",
    "Description": "C15r11c3: Rexulti - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equi",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r11c4",
    "Description": "C15r11c4: Auvelity - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equ",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r11c5",
    "Description": "C15r11c5: Spravato - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equ",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r11c6",
    "Description": "C15r11c6: IV Ketamine - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r11c7",
    "Description": "C15r11c7: TMS - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivale",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r11c8",
    "Description": "C15r11c8: ECT - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivale",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r11c9",
    "Description": "C15r11c9: All treatments equally - Availability of patient cost support programs - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all trea",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r12c1",
    "Description": "C15r12c1: Trintellix - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, pl",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r12c2",
    "Description": "C15r12c2: Vraylar - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, pleas",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r12c3",
    "Description": "C15r12c3: Rexulti - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, pleas",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r12c4",
    "Description": "C15r12c4: Auvelity - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, plea",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r12c5",
    "Description": "C15r12c5: Spravato - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, plea",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r12c6",
    "Description": "C15r12c6: IV Ketamine - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, p",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r12c7",
    "Description": "C15r12c7: TMS - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please se",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r12c8",
    "Description": "C15r12c8: ECT - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are equivalent, please se",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r12c9",
    "Description": "C15r12c9: All treatments equally - Financial benefit to my practice - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments are eq",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C15r13c1",
    "Description": "C15r13c1: Trintellix - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all tre",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix"
  },
  {
    "Column": "C15r13c2",
    "Description": "C15r13c2: Vraylar - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatm",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar"
  },
  {
    "Column": "C15r13c3",
    "Description": "C15r13c3: Rexulti - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatm",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti"
  },
  {
    "Column": "C15r13c4",
    "Description": "C15r13c4: Auvelity - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treat",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity"
  },
  {
    "Column": "C15r13c5",
    "Description": "C15r13c5: Spravato - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treat",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato"
  },
  {
    "Column": "C15r13c6",
    "Description": "C15r13c6: IV Ketamine - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all tr",
    "Answer_Options": "0=NO TO: IV Ketamine,1=IV Ketamine"
  },
  {
    "Column": "C15r13c7",
    "Description": "C15r13c7: TMS - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments",
    "Answer_Options": "0=NO TO: TMS,1=TMS"
  },
  {
    "Column": "C15r13c8",
    "Description": "C15r13c8: ECT - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute. If all treatments",
    "Answer_Options": "0=NO TO: ECT,1=ECT"
  },
  {
    "Column": "C15r13c9",
    "Description": "C15r13c9: All treatments equally - Easier to refer patients for treatment at another location - For the treatments below, please select which is most effective at delivering on each given attribute. You can select one or more treatments for each attribute",
    "Answer_Options": "0=NO TO: All treatments equally,1=All treatments equally"
  },
  {
    "Column": "C16r1",
    "Description": "C16r1: Considering the benefits & drawbacks of Spravato, it is “worth it” for my patients to try Spravato - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r2",
    "Description": "C16r2: Considering the benefits & drawbacks of Spravato, it is “worth it” for my practice to offer Spravato as a treatment - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r3",
    "Description": "C16r3: It’s easy to identify TRD patients who are medically appropriate for Spravato - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r4",
    "Description": "C16r4: The ability to use Spravato monotherapy makes it an appealing option for use in my TRD patients - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r5",
    "Description": "C16r5: On balance, the need for REMS to prescribe Spravato is a positive thing for my practice and my patients - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r6",
    "Description": "C16r6: Spravato is an innovative treatment - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r7",
    "Description": "C16r7: I expect to reserve Spravato for only my most severe TRD patients - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r8",
    "Description": "C16r8: I trust that if I refer a patient for Spravato, that patient will ultimately be prescribed Spravato - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r9",
    "Description": "C16r9: Referring a patient for Spravato is a way to ensure they get treated by a psychiatrist faster than they might have otherwise - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C16r10",
    "Description": "C16r10: Spravato fulfills an unmet need in my care of TRD patients - How much do you agree with the following statements?[res Spravato_hyperlink]",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "C16"
  },
  {
    "Column": "C17r1",
    "Description": "C17r1: I currently have, or could create, physical space in my office to administer Spravato - Which of the following describes your practice?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I currently have, or could create, physical space in my office to administer Spravato,1=I currently have, or could create, physical space in my office to administer Spravato",
    "ParentQuestion": "C17"
  },
  {
    "Column": "C17r2",
    "Description": "C17r2: I currently have, or could create, physical space in my office to administer TMS - Which of the following describes your practice?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I currently have, or could create, physical space in my office to administer TMS,1=I currently have, or could create, physical space in my office to administer TMS",
    "ParentQuestion": "C17"
  },
  {
    "Column": "C17r3",
    "Description": "C17r3: I have very easy access to a referral network for Spravato should I choose to refer patients for treatment - Which of the following describes your practice?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I have very easy access to a referral network for Spravato should I choose to refer patients for treatment,1=I have very easy access to a referral network for Spravato should I choose to refer patients for treatment",
    "ParentQuestion": "C17"
  },
  {
    "Column": "C17r4",
    "Description": "C17r4: I have dedicated staff who handles navigating prior authorizations and reimbursement for medications - Which of the following describes your practice?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: I have dedicated staff who handles navigating prior authorizations and reimbursement for medications,1=I have dedicated staff who handles navigating prior authorizations and reimbursement for medications",
    "ParentQuestion": "C17"
  },
  {
    "Column": "C17r5",
    "Description": "C17r5: My practice has institutional norms, guidelines and/or formularies I’m expected to follow when treating TRD patients - Which of the following describes your practice?[res Spravato_hyperlink]",
    "Answer_Options": "0=NO TO: My practice has institutional norms, guidelines and/or formularies I’m expected to follow when treating TRD pat,1=My practice has institutional norms, guidelines and/or formularies I’m expected to follow when treating TRD patients",
    "ParentQuestion": "C17"
  },
  {
    "Column": "C18r1",
    "Description": "C18r1: Oral antidepressants don't work for everyone: When patients try their third line of treatment, 86% do not achieve remission - We’d now like to show you a few brief statements about Spravato. Please read each statement below and evaluate each in t",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "C18r2",
    "Description": "C18r2: SPRAVATO is a non-competitive NMDA receptor antagonist, leading to increased glutamate release in the synapse. SPRAVATO targets glutamate, the most abundant excitatory neurotransmitter in the brain - We’d now like to show you a few brief statemen",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "C18r3",
    "Description": "C18r3: SPRAVATO alone or in combinations offers rapid reduction in the burden of depressive symptoms at Week 4 and as early as 24 hours, with numerical improvement across all 10 MADRS items at Day 28 - We’d now like to show you a few brief statements ab",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "C18r4",
    "Description": "C18r4: SPRAVATO has an established safety profile with >90% of side effects resolving on the same day - We’d now like to show you a few brief statements about Spravato. Please read each statement below and evaluate each in terms of what information woul",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "C18r5",
    "Description": "C18r5: SPRAVATO has a low incidence of weight gain and sexual dysfunction with no signal of tardive dyskinesia - We’d now like to show you a few brief statements about Spravato. Please read each statement below and evaluate each in terms of what informa",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "C18r6",
    "Description": "C18r6: SPRAVATO delivers durability over time demonstrated through sustained and consistent MADRS & PHQ9 scores out to 5 years - We’d now like to show you a few brief statements about Spravato. Please read each statement below and evaluate each in terms",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "C18r7",
    "Description": "C18r7: SPRAVATO offers more freedom through flexibility in treatment approach, dosing, and post-induction frequency - We’d now like to show you a few brief statements about Spravato. Please read each statement below and evaluate each in terms of what in",
    "Answer_Options": "1=Not at all important,2=Slightly important,3=Moderately important,4=Very important,5=Extremely important",
    "ParentQuestion": "C18"
  },
  {
    "Column": "D1r1",
    "Description": "D1r1: I regularly talk to my TRD patients about patient support programs for their condition - How much do you agree with the following statements about manufacturer-provided patient support programs?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r2",
    "Description": "D1r2: My office staff regularly talks to my TRD patients about patient support programs for their condition - How much do you agree with the following statements about manufacturer-provided patient support programs?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r3",
    "Description": "D1r3: The availability of patient support programs has changed the way I prescribe for TRD - How much do you agree with the following statements about manufacturer-provided patient support programs?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r4",
    "Description": "D1r4: TRD patients who participate in patient support programs find them valuable - How much do you agree with the following statements about manufacturer-provided patient support programs?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r5",
    "Description": "D1r5: I am very aware of what patient support programs are out there for my TRD patients - How much do you agree with the following statements about manufacturer-provided patient support programs?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D2r1",
    "Description": "D2r1: Aware of patient support programs for patients with treatment-resistant MDD - What percentage of your TRD patients would you say are…",
    "Answer_Options": "NA",
    "ParentQuestion": "D2"
  },
  {
    "Column": "D2r2",
    "Description": "D2r2: Enrolled in one or more patient support programs for patients with treatment-resistant MDD - What percentage of your TRD patients would you say are…",
    "Answer_Options": "NA",
    "ParentQuestion": "D2"
  },
  {
    "Column": "D2r3",
    "Description": "D2r3: Neither aware nor enrolled in patient support programs for patients with treatment-resistant MDD - What percentage of your TRD patients would you say are…",
    "Answer_Options": "NA",
    "ParentQuestion": "D2"
  },
  {
    "Column": "D3r1",
    "Description": "D3r1: Trintellix - Which, if any, of the following medications offer a patient support program, to the best of your knowledge?",
    "Answer_Options": "0=NO TO: Trintellix,1=Trintellix",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r2",
    "Description": "D3r2: Vraylar - Which, if any, of the following medications offer a patient support program, to the best of your knowledge?",
    "Answer_Options": "0=NO TO: Vraylar,1=Vraylar",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r3",
    "Description": "D3r3: Rexulti - Which, if any, of the following medications offer a patient support program, to the best of your knowledge?",
    "Answer_Options": "0=NO TO: Rexulti,1=Rexulti",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r4",
    "Description": "D3r4: Auvelity - Which, if any, of the following medications offer a patient support program, to the best of your knowledge?",
    "Answer_Options": "0=NO TO: Auvelity,1=Auvelity",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r5",
    "Description": "D3r5: Spravato - Which, if any, of the following medications offer a patient support program, to the best of your knowledge?",
    "Answer_Options": "0=NO TO: Spravato,1=Spravato",
    "ParentQuestion": "D3"
  },
  {
    "Column": "E1",
    "Description": "E1: On average, how many hours per month in total do you spend on keeping abreast of medical developments or medical education, specifically related to MDD / TRD? This would include any of the following activities: Reading medical journals Reviewing new c",
    "Answer_Options": "NA"
  },
  {
    "Column": "E2r1",
    "Description": "E2r1: Interactions with sales representatives - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Interactions with sales representatives,1=Interactions with sales representatives",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r2",
    "Description": "E2r2: Interactions with Medical Science Liaisons - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Interactions with Medical Science Liaisons,1=Interactions with Medical Science Liaisons",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r3",
    "Description": "E2r3: Electronic detailing / e-detailing (online or phone interaction with sales representative) - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Electronic detailing / e-detailing (online or phone interaction with sales representative),1=Electronic detailing / e-detailing (online or phone interaction with sales representative)",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r4",
    "Description": "E2r4: In-person congresses / conferences - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: In-person congresses / conferences,1=In-person congresses / conferences",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r5",
    "Description": "E2r5: Video conferences / webcasts - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Video conferences / webcasts,1=Video conferences / webcasts",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r6",
    "Description": "E2r6: Podcasts - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Podcasts,1=Podcasts",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r7",
    "Description": "E2r7: Dinner meetings / roundtable discussions - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Dinner meetings / roundtable discussions,1=Dinner meetings / roundtable discussions",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r8",
    "Description": "E2r8: Disease-specific websites - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Disease-specific websites,1=Disease-specific websites",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r9",
    "Description": "E2r9: Influential peers or specialists in the field - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Influential peers or specialists in the field,1=Influential peers or specialists in the field",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r10",
    "Description": "E2r10: CME programs - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: CME programs,1=CME programs",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r11",
    "Description": "E2r11: General health & medical websites (i.e., uptodate.com, webmd.com) - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: General health & medical websites (i.e., uptodate.com, webmd.com),1=General health & medical websites (i.e., uptodate.com, webmd.com)",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r12",
    "Description": "E2r12: Peer-reviewed, published clinical study results - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Peer-reviewed, published clinical study results,1=Peer-reviewed, published clinical study results",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r13",
    "Description": "E2r13: Digital tools / apps you would access on your mobile phone or tablet - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Digital tools / apps you would access on your mobile phone or tablet,1=Digital tools / apps you would access on your mobile phone or tablet",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r14",
    "Description": "E2r14: Peer-to-peer - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Peer-to-peer,1=Peer-to-peer",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r15",
    "Description": "E2r15: Patient testimonials - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Patient testimonials,1=Patient testimonials",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r16",
    "Description": "E2r16: Press releases - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Press releases,1=Press releases",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r17",
    "Description": "E2r17: News articles - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: News articles,1=News articles",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E2r18",
    "Description": "E2r18: Social media - From which sources would you be most receptive to receiving information about MDD / TRD?",
    "Answer_Options": "0=NO TO: Social media,1=Social media",
    "ParentQuestion": "E2"
  },
  {
    "Column": "E3",
    "Description": "E3: In a typical year, how many medical conferences, congresses or seminars do you attend where MDD / TRD is a topic of discussion?",
    "Answer_Options": "NA"
  },
  {
    "Column": "E4",
    "Description": "E4: How accessible is your practice to pharmaceutical sales representatives?",
    "Answer_Options": "1=Does not restrict access at all,2=Allows limited access (e.g., limited to certain days and/or hours only),3=Does not allow access"
  },
  {
    "Column": "E5",
    "Description": "E5: In a typical 3-month period, approximately how many representatives do you personally see from pharmaceutical companies? Please think only about those representatives with whom you have some type of interaction, whether it is signing for samples, disc",
    "Answer_Options": "NA"
  },
  {
    "Column": "E6",
    "Description": "E6: In the past 3 months, approximately how many times have you been visited by a pharmaceutical representative specifically from Spravato?",
    "Answer_Options": "NA"
  },
  {
    "Column": "E7r1",
    "Description": "E7r1: Twitter/X - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: Twitter/X,1=Twitter/X",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r2",
    "Description": "E7r2: Facebook - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: Facebook,1=Facebook",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r3",
    "Description": "E7r3: Instagram - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: Instagram,1=Instagram",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r4",
    "Description": "E7r4: TikTok - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: TikTok,1=TikTok",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r5",
    "Description": "E7r5: YouTube - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: YouTube,1=YouTube",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r6",
    "Description": "E7r6: LinkedIn - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: LinkedIn,1=LinkedIn",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r7",
    "Description": "E7r7: Streaming TV platforms (e.g., Netflix, Hulu, MAX, etc.) - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: Streaming TV platforms (e.g., Netflix, Hulu, MAX, etc.),1=Streaming TV platforms (e.g., Netflix, Hulu, MAX, etc.)",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r8",
    "Description": "E7r8: Cable television - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: Cable television,1=Cable television",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r9",
    "Description": "E7r9: Other (specify) - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: Other (specify),1=Other (specify)",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r10",
    "Description": "E7r10: None - In the past year, which of the following media platforms have you used?",
    "Answer_Options": "0=NO TO: None,1=None",
    "ParentQuestion": "E7"
  },
  {
    "Column": "E7r9oe",
    "Description": "E7r9oe: In the past year, which of the following media platforms have you used? - Other (specify)",
    "Answer_Options": "NA",
    "ParentQuestion": "E7"
  },
  {
    "Column": "hE7Count",
    "Description": "hE7Count: E7: # of items selected",
    "Answer_Options": "NA"
  },
  {
    "Column": "E8r1",
    "Description": "E8r1: Twitter/X - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r2",
    "Description": "E8r2: Facebook - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r3",
    "Description": "E8r3: Instagram - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r4",
    "Description": "E8r4: TikTok - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r5",
    "Description": "E8r5: YouTube - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r6",
    "Description": "E8r6: LinkedIn - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r7",
    "Description": "E8r7: Streaming TV platforms (e.g., Netflix, Hulu, MAX, etc.) - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r8",
    "Description": "E8r8: Cable television - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "E8r9",
    "Description": "E8r9: $ {E7.r9.open} - How often do you use each of the following platforms?",
    "Answer_Options": "1=Daily,2=A few times per week,3=Once a week,4=A few times a month,5=Once a month or less",
    "ParentQuestion": "E8"
  },
  {
    "Column": "F13r1",
    "Description": "F13r1: I always try to choose treatments that will have the lowest cost to the patient - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F13r2",
    "Description": "F13r2: I’m willing to fight against cost and access issues to get my patients the best treatment possible - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F13r3",
    "Description": "F13r3: I always try to choose treatments that I’m confident my patients will have insurance coverage for - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F13r4",
    "Description": "F13r4: I am involved in overseeing the business/financial aspects of my institution/practice - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F13r5",
    "Description": "F13r5: I am very conscious of the financial implications of my treatment decisions on my institution/practice - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F13r6",
    "Description": "F13r6: Financial considerations for my institution/practice may affect the treatments I prescribe or recommend - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F13r7",
    "Description": "F13r7: Financial considerations for my institution/practice make me reluctant to refer a patient for care with another provider - How much do you agree with the following statements, when thinking specifically about the treatment of TRD?",
    "Answer_Options": "1=Strongly disagree,2=Somewhat disagree,3=Neutral,4=Somewhat agree,5=Strongly agree",
    "ParentQuestion": "F13"
  },
  {
    "Column": "F14r1",
    "Description": "F14r1: I’m an early adopter of new technology - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r2",
    "Description": "F14r2: I like wearable technology (e.g., smart watches, fitness trackers, etc.) - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r3",
    "Description": "F14r3: I’m a risk-taker when it comes to recreational activities - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r4",
    "Description": "F14r4: I prefer a challenge in my professional life to something easy - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r5",
    "Description": "F14r5: In my professional life, I learn by doing - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r6",
    "Description": "F14r6: I’m a planner - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r7",
    "Description": "F14r7: My family comes first, before my work - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r8",
    "Description": "F14r8: I’m willing to wait a long time for something I’m truly interested in - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r9",
    "Description": "F14r9: I’m very loyal to brands I like - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r10",
    "Description": "F14r10: I often make impulse purchases - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r11",
    "Description": "F14r11: I often buy products or services I see on social media - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "F14r12",
    "Description": "F14r12: I am comfortable talking about my mental health - To what extent do each of the following statements describe you?",
    "Answer_Options": "1=Does not describe me at all,2=Somewhat describes me,3=Completely describes me",
    "ParentQuestion": "F14"
  },
  {
    "Column": "dummyF16Rand",
    "Description": "dummyF16Rand: DUMMY F16 RANDOMIZATION",
    "Answer_Options": "1=Straight,2=Reverse"
  },
  {
    "Column": "dummyF16ROT",
    "Description": "dummyF16ROT: dummyF16ROT",
    "Answer_Options": "1=I am adventurous,2=I am reserved,3=I am an introvert,4=I am an extrovert,5=I want to feel like part of a group/community,6=I like to keep to myself most of the time,7=I feel that each day is a challenge,8=I feel that each day is an opportunity,9=I like to look fashionable and put effort into my appearance,10=I am unconcerned with fashion and appearance"
  },
  {
    "Column": "F16r1",
    "Description": "F16r1: I am adventurous / I am reserved - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "F16"
  },
  {
    "Column": "F16r2",
    "Description": "F16r2: I am an introvert / I am an extrovert - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "F16"
  },
  {
    "Column": "F16r3",
    "Description": "F16r3: I want to feel like part of a group/community / I like to keep to myself most of the time - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "F16"
  },
  {
    "Column": "F16r4",
    "Description": "F16r4: I feel that each day is a challenge / I feel that each day is an opportunity - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "F16"
  },
  {
    "Column": "F16r5",
    "Description": "F16r5: I like to look fashionable and put effort into my appearance / I am unconcerned with fashion and appearance - For each pair of statements, please select the one you most identify with.",
    "Answer_Options": "1=Much more - Statement A,2=More - Statement A,3=Neutral,4=More - Statement B,5=Much more - Statement B",
    "ParentQuestion": "F16"
  },
  {
    "Column": "F1",
    "Description": "F1: [pipe:S7Pipe]",
    "Answer_Options": "NA"
  },
  {
    "Column": "F2",
    "Description": "F2: In which state do you have your license to practice?",
    "Answer_Options": "1=Alaska,2=Alabama,3=Arkansas,4=Arizona,5=California,6=Colorado,7=Connecticut,8=District of Columbia,9=Delaware,10=Florida,11=Georgia,12=Hawaii,13=Iowa,14=Idaho,15=Illinois,16=Indiana,17=Kansas,18=Kentucky,19=Louisiana,20=Massachusetts,21=Maryland,22=Maine,23=Michigan,24=Minnesota,25=Missouri,26=Mississippi,27=Montana,28=North Carolina,29=North Dakota,30=Nebraska,31=New Hampshire,32=New Jersey,33=New Mexico,34=Nevada,35=New York,36=Ohio,37=Oklahoma,38=Oregon,39=Pennsylvania,40=Rhode Island,41=South Carolina,42=South Dakota,43=Tennessee,44=Texas,45=Utah,46=Virginia,47=Vermont,48=Washington,49=Wisconsin,50=West Virginia,51=Wyoming"
  },
  {
    "Column": "F3",
    "Description": "F3: Which of the following best describes the setting in which you practice?",
    "Answer_Options": "1=Urban,2=Suburban,3=Rural"
  },
  {
    "Column": "F4",
    "Description": "F4: Are you….",
    "Answer_Options": "1=Male,2=Female,3=Non-binary,4=Prefer to self-describe,5=Prefer not to answer"
  },
  {
    "Column": "F5",
    "Description": "F5: What is your age?",
    "Answer_Options": "18=18,19=19,20=20,21=21,22=22,23=23,24=24,25=25,26=26,27=27,28=28,29=29,30=30,31=31,32=32,33=33,34=34,35=35,36=36,37=37,38=38,39=39,40=40,41=41,42=42,43=43,44=44,45=45,46=46,47=47,48=48,49=49,50=50,51=51,52=52,53=53,54=54,55=55,56=56,57=57,58=58,59=59,60=60,61=61,62=62,63=63,64=64,65=65,66=66,67=67,68=68,69=69,70=70,71=71,72=72,73=73,74=74,75=75,76=76,77=77,78=78,79=79,80=80,81=81,82=82,83=83,84=84,85=85,86=86,87=87,88=88,89=89,90=90,91=91,92=92,93=93,94=94,95=95,96=96,97=97,98=98,99=99,100=100"
  },
  {
    "Column": "F6r1",
    "Description": "F6r1: Asian - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: Asian,1=Asian",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F6r2",
    "Description": "F6r2: Black or African American - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: Black or African American,1=Black or African American",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F6r3",
    "Description": "F6r3: Hispanic, Latinx, or of Spanish origin - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: Hispanic, Latinx, or of Spanish origin,1=Hispanic, Latinx, or of Spanish origin",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F6r4",
    "Description": "F6r4: Native American or Alaskan Native - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: Native American or Alaskan Native,1=Native American or Alaskan Native",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F6r5",
    "Description": "F6r5: Native Hawaiian or Other Pacific Islander - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: Native Hawaiian or Other Pacific Islander,1=Native Hawaiian or Other Pacific Islander",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F6r6",
    "Description": "F6r6: White - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: White,1=White",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F6r7",
    "Description": "F6r7: Other - Which of the following best describes your race or ethnicity?",
    "Answer_Options": "0=NO TO: Other,1=Other",
    "ParentQuestion": "F6"
  },
  {
    "Column": "F7r1",
    "Description": "F7r1: Physicians - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "Answer_Options": "NA",
    "ParentQuestion": "F7"
  },
  {
    "Column": "F7r5",
    "Description": "F7r5: Therapists - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "Answer_Options": "NA",
    "ParentQuestion": "F7"
  },
  {
    "Column": "F7r2",
    "Description": "F7r2: Nurses or Medical Assistants - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "Answer_Options": "NA",
    "ParentQuestion": "F7"
  },
  {
    "Column": "F7r3",
    "Description": "F7r3: Nurse Practitioners/Physicians Assistants - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "Answer_Options": "NA",
    "ParentQuestion": "F7"
  },
  {
    "Column": "F7r4",
    "Description": "F7r4: Administrative Staff - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice? Please enter one answer for each group.",
    "Answer_Options": "NA",
    "ParentQuestion": "F7"
  },
  {
    "Column": "hF7Sum",
    "Description": "hF7Sum: F7: Sum of staff",
    "Answer_Options": "NA"
  },
  {
    "Column": "F8",
    "Description": "F8: How would you describe the organization that owns your practice?",
    "Answer_Options": "1=Private Practice,2=Integrated Delivery Network / Integrated Delivery System,3=Accountable Care Organization (ACO),4=Community Health System / Hospital System,5=Academic Health System / Hospital System,6=Independent Medical Group,7=Other"
  },
  {
    "Column": "hF8NET",
    "Description": "hF8NET: F8: independent NET",
    "Answer_Options": "1=Private Practice/Independent Medical Group,2=Integrated Delivery Network / Integrated Delivery System,3=Accountable Care Organization (ACO),4=Community Health System / Hospital System,5=Academic Health System / Hospital System,7=Other"
  },
  {
    "Column": "F9",
    "Description": "F9: Does your practice own one or more Transcranial Magnetic Stimulation (TMS) machines?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "F10",
    "Description": "F10: Do you have any direct ownership stake in your practice?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "F15",
    "Description": "F15: Does your practice bill commercial insurance directly for services?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "F11",
    "Description": "F11: Which of the following best represents the ability of your TRD patients to afford their medications?",
    "Answer_Options": "1=Most can easily afford their medications,2=Some can easily afford their medications,3=Few can easily afford their medications"
  },
  {
    "Column": "F12r1",
    "Description": "F12r1: No coverage / cash paying - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "F12r2",
    "Description": "F12r2: Commercial insurance (HMO, PPO, or other private insurance – may be a Medicare supplement) - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "F12r3",
    "Description": "F12r3: Medicaid / Public Aid - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "F12r4",
    "Description": "F12r4: Traditional Medicare - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "F12r5",
    "Description": "F12r5: Medicare Advantage - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "F12r6",
    "Description": "F12r6: VA (Veterans’ Administration) or Department of Defense - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "F12r7",
    "Description": "F12r7: Other - Approximately what percent of your TRD patients have the following as their primary healthcare coverage?",
    "Answer_Options": "NA",
    "ParentQuestion": "F12"
  },
  {
    "Column": "hF12Sum",
    "Description": "hF12Sum: F12: Medicare NET – sum of 4+5",
    "Answer_Options": "NA"
  },
  {
    "Column": "qtime",
    "Description": "qtime: Total Interview Time",
    "Answer_Options": "NA"
  },
  {
    "Column": "hLIST_TYPE",
    "Description": "hLIST_TYPE: Hidden in live",
    "Answer_Options": "1=ON-LIST,2=OFF-LIST"
  },
  {
    "Column": "jnj_id",
    "Description": "jnj_id: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "npi_id",
    "Description": "npi_id: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Target_Prio",
    "Description": "Target_Prio: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "referrer_segment",
    "Description": "referrer_segment: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "prim_spclt_nm",
    "Description": "prim_spclt_nm: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "cust_subtyp_nm",
    "Description": "cust_subtyp_nm: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "birth_dt",
    "Description": "birth_dt: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "gndr_cd",
    "Description": "gndr_cd: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPR_Treater_Q1_25_Mood_Call_Plan",
    "Description": "SPR_Treater_Q1_25_Mood_Call_Plan: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "TD_Call_Plan_Q1_25",
    "Description": "TD_Call_Plan_Q1_25: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "HY_Call_Plan_Q1_25",
    "Description": "HY_Call_Plan_Q1_25: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "NEW_KS",
    "Description": "NEW_KS: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "no_of_Calls_3_1_23_2_28_25",
    "Description": "no_of_Calls_3_1_23_2_28_25: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Speaker_Program_Attendance_3_1_28_2_28_25",
    "Description": "Speaker_Program_Attendance_3_1_28_2_28_25: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Acct_Affiliated_Treater",
    "Description": "Acct_Affiliated_Treater: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Call",
    "Description": "Call: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Treater",
    "Description": "Treater: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "AAID",
    "Description": "AAID: Captured variable",
    "Answer_Options": "NA"
  }
]